Eli Lilly and Company (LLY) Breaks Ground On $5B Integrated ADC Plant In Virginia

METiS TechBio (HK-listed) and Eli Lilly (NYSE: LLY) partnered to develop AI-powered drug delivery tech, focusing on lipid nanoparticles. METiS could receive up to $1.1B in milestone payments and royalties. Lilly previously partnered with Insilico Medicine (HK-listed) for AI drug discovery, with a deal worth up to $2.75B.

Eli Lilly began construction on a $6.5B Houston site to produce oral GLP-1 medications, including its obesity drug orforglipron. The facility is part of a $50B commitment to domestic pharmaceutical production, creating 4,600 jobs and partnering with San Jacinto College for workforce training. According to the company, this is the largest active pharmaceutical ingredient project in Texas history.

Eli Lilly (NYSE:LLY) began construction on a $5B Virginia facility to produce cancer treatments, creating 650 jobs. The site is part of 10 new U.S. manufacturing sites announced since 2020. Lilly also committed $40M to a training network for pharmaceutical careers.

Eli Lilly filed lawsuits against five defendants, including online retailers and clinics, alleging they market and sell products containing retatrutide, an unapproved drug. Lilly seeks injunctions and damages, citing consumer protection and unfair competition laws. The cases highlight concerns about marketing practices, disclaimers, and regulatory compliance in the peptide market.

Daniel Morgenstern, a staff physician at The Hospital for Sick Children, highlighted the success of selpercatinib, a RET inhibitor developed by Loxo Oncology (acquired by Eli Lilly), in treating rare pediatric cancers. The drug showed impressive response and disease control rates in a pediatric phase I/II study published in the Journal of Clinical Oncology. Morgenstern emphasized the need for similar targeted treatments for other pediatric cancers.

METiS and Lilly have partnered to develop next-generation lipid nanoparticle (LNP) delivery solutions. METiS will receive an upfront payment in the low double-digit millions and up to $1.1 billion in milestone payments, plus royalties. The collaboration leverages METiS' AI-driven AiLNP platform for lipid discovery and Lilly's drug development expertise.